This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ball, K. Articles by Bagg, J. Search for Related Content PubMed PubMed Citation Articles by Ball, K. Articles by Bagg, J. Social Bookmarking                         What's this?

Fluconazole sensitivities of Candida species isolated from the mouths of terminally ill cancer patients

University of Glasgow Dental School, Glasgow, Scotland

M. Petrina Sweeney, BDS, MSc (Med Sci)

University of Glasgow Dental School, Glasgow, Scotland, Renfrewshire Healthcare NHS Trust, Dykebar Hospital, Paisley, Scotland

Wendy P. Baxter, FRCP (Glasg)

ACCORD Hospice, Paisley, Scotland

Jeremy Bagg, PhD, FDS, FRCPath

University of Glasgow Dental School, Glasgow, Scotland

Oral candidosis is common in advanced cancer and is often treated with the systemic triazole antifungal drug fluconazole. This study examined the species of yeast present in the mouths of 30 patients with advanced cancer and determined their sensitivity to fluconazole. Thirty-five yeast isolates were collected from a total of 25 (83 percent) of the patients sampled. The two most common species were Candida albicans (15 isolates) and C. glabrata (11 isolates)—with smaller numbers of C. tropicalis, C. parapsilosis, C. guilliermondii, C. inconspicua, and Saccharomyces cerevisiae. The minimal inhibitory concentrations (MIC) of fluconazole for the strains of C. albicans were generally low (median 0.19µg/ml) but were considerably higher for C. glabrata (median 2µg/ml). The remaining species demonstrated MICs similar to those for C. albicans, with the exceptions of C. inconspicua and Saccharomyces cerevisiae, which were relatively insensitive. In conclusion, non-albicans yeasts are common in the mouths of patients with advanced cancer and these may have reduced sensitivity to fluconazole. Mycological diagnosis is a valuable aid to management.

American Journal of Hospice and Palliative Medicine®, Vol. 15, No. 6, 315-319 (1998)
DOI: 10.1177/104990919801500605


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?